These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 10561251)

  • 1. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.
    Adkins D; Brown R; Trinkaus K; Maziarz R; Luedke S; Freytes C; Needles B; Wienski D; Fracasso P; Pluard T; Moriconi W; Ryan T; Hoelzer K; Safdar S; Rearden T; Rodriguez G; Khoury H; Vij R; DiPersio J
    J Clin Oncol; 1999 Jul; 17(7):2006-14. PubMed ID: 10561251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
    Somlo G; Doroshow JH; Forman SJ; Odom-Maryon T; Lee J; Chow W; Hamasaki V; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Simpson J; Molina A
    J Clin Oncol; 1997 Aug; 15(8):2882-93. PubMed ID: 9256132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
    Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D
    Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
    Cagnoni PJ; Nieto Y; Shpall EJ; Bearman SI; Barón AE; Ross M; Matthes S; Dunbar SE; Jones RB
    J Clin Oncol; 1998 May; 16(5):1661-8. PubMed ID: 9586876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
    Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.
    Somlo G; Frankel P; Chow W; Leong L; Margolin K; Morgan R; Shibata S; Chu P; Forman S; Lim D; Twardowski P; Weitzel J; Alvarnas J; Kogut N; Schriber J; Fermin E; Yen Y; Damon L; Doroshow JH
    J Clin Oncol; 2004 May; 22(10):1839-48. PubMed ID: 15143076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
    Ayash LJ; Elias A; Ibrahim J; Schwartz G; Wheeler C; Reich E; Lynch C; Warren D; Shapiro C; Richardson P; Hurd D; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1998 Mar; 16(3):1000-7. PubMed ID: 9508183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
    García-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gómez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortés-Funes H
    J Clin Oncol; 1997 Oct; 15(10):3178-84. PubMed ID: 9336353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
    Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
    Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer.
    Yalamanchili K; Lalmuanpuii J; Waheed F; Farjami S; Kancherla R; Qureshi Z; Hoang A; Khaled Y; Lake D; Puccio C; Chun HG; Seiter K; Ahmed T
    Anticancer Res; 2008; 28(5B):3139-42. PubMed ID: 19031971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
    Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
    J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California.
    Damon LE; Hu WW; Stockerl-Goldstein KE; Blume KG; Wolf JL; Gold E; Cecchi GR; Irwin D; Glaspy J; Territo I; Miller W; Mason JR; Linker CA
    Biol Blood Marrow Transplant; 2000; 6(5):496-505. PubMed ID: 11063378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
    Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
    Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
    Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
    Schneeweiss A; Hensel M; Goerner R; Khbeis T; Hohaus S; Egerer G; Solomayer E; Haas R; Grischke EM; Bastert G; Ho AD
    Stem Cells; 2001; 19(2):151-60. PubMed ID: 11239170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.